Scientific article
Open access

Traitement d’éradication d’Helicobacter pylori en 2019

Other titleFirst line eradication treatment of Helicobacter pylori in 2019
Published inRevue médicale suisse, vol. 15, no. 667, p. 1854-1858
Publication date2019-10-16

Helicobacter pylori infection is associated with chronic gastric inflammation, peptic ulcer and an increased risk of gastric cancer. Helicobacter eradication traditionally consists of an empirical therapy combining clarithromycine, amoxicillin and proton pump inhibitors. However, this classic therapy needs to be reassessed because of the raising prevalence of clarithromycine resistance. Various alternative eradication treatments have been studied. This article aims to review the recommended alternatives and the different factors to guide the most appropriate first line eradication therapy.

  • Amoxicillin / pharmacology
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clarithromycin / pharmacology
  • Clarithromycin / therapeutic use
  • Drug Resistance, Bacterial / drug effects
  • Drug Therapy, Combination
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / drug effects
  • Humans
  • Proton Pump Inhibitors / pharmacology
  • Proton Pump Inhibitors / therapeutic use
Citation (ISO format)
GRESSOT, Pablo et al. Traitement d’éradication d’Helicobacter pylori en 2019. In: Revue médicale suisse, 2019, vol. 15, n° 667, p. 1854–1858. doi: 10.53738/REVMED.2019.15.667.1854
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation06/15/2022 9:14:04 AM
First validation06/05/2023 7:40:06 AM
Update time06/05/2023 7:40:06 AM
Status update06/05/2023 7:40:06 AM
Last indexation08/31/2023 11:42:27 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack